Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹944 Cr
Revenue (TTM)
₹593 Cr
Net Profit (TTM)
₹33 Cr
ROE
14 %
ROCE
16.2 %
P/E Ratio
28.9
P/B Ratio
3.6
Industry P/E
44.74
EV/EBITDA
13.4
Div. Yield
0 %
Debt to Equity
1.2
Book Value
₹478
EPS
₹66.5
Face value
10
Shares outstanding
5,472,690
CFO
₹-31.33 Cr
EBITDA
₹172.77 Cr
Net Profit
₹65.13 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fredun Pharma
| 9.3 | 6.2 | 12.3 | 146.8 | 30.4 | 30.5 | 63.7 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Fredun Pharma
| 115.0 | -14.5 | -22.4 | 32.5 | 107.1 | 84.6 | -34.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fredun Pharma
|
1,724.6 | 943.8 | 593.5 | 32.7 | 12.8 | 21.9 | 28.9 | 3.6 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable... alkaloids; Read more
Incorporated
1987
Chairman
Daulat Medhora
Managing Director
Fredun Medhora
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Fredun Pharmaceuticals Ltd is ₹1,724.55 (BSE) as of 02-Apr-2026 IST. Fredun Pharmaceuticals Ltd has given a return of 30.43% in the last 3 years.
The P/E ratio of Fredun Pharmaceuticals Ltd is 28.88 times as on 02-Apr-2026, a 35 discount to its peers’ median range of 44.74 times.
The P/B ratio of Fredun Pharmaceuticals Ltd is 3.61 times as on 02-Apr-2026, a 16 premium to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
15.99
|
2.23
|
|
2024
|
21.57
|
2.81
|
|
2023
|
32.60
|
4.00
|
|
2022
|
64.04
|
5.98
|
|
2021
|
91.79
|
4.29
|
The 52-week high and low of Fredun Pharmaceuticals Ltd are Rs 1,999.00 and Rs 635.05 as of 03-Apr-2026.
Fredun Pharmaceuticals Ltd has a market capitalisation of ₹ 944 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Fredun Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹8.35
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.